User profiles for K. L. Ligon
![]() | Keith L. LigonAssociate Professor, Harvard Medical School Verified email at dfci.harvard.edu Cited by 53812 |
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Malignant astrocytic gliomas such as glioblastoma are the most common and lethal
intracranial tumors. These cancers exhibit a relentless malignant progression characterized by …
intracranial tumors. These cancers exhibit a relentless malignant progression characterized by …
Emerging insights into the molecular and cellular basis of glioblastoma
Glioblastoma is both the most common and lethal primary malignant brain tumor. Extensive
multiplatform genomic characterization has provided a higher-resolution picture of the …
multiplatform genomic characterization has provided a higher-resolution picture of the …
[HTML][HTML] Glioblastoma targeted therapy: updated approaches from recent biological insights
Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …
representing a highly heterogeneous group of neoplasms that are among the most …
[PDF][PDF] An integrative model of cellular states, plasticity, and genetics for glioblastoma
Diverse genetic, epigenetic, and developmental programs drive glioblastoma, an incurable
and poorly understood tumor, but their precise characterization remains challenging. Here, …
and poorly understood tumor, but their precise characterization remains challenging. Here, …
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Glioblastoma (GBM) is a highly lethal brain tumour presenting as one of two subtypes with
distinct clinical histories and molecular profiles. The primary GBM subtype presents acutely as …
distinct clinical histories and molecular profiles. The primary GBM subtype presents acutely as …
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Targeted therapies that inhibit receptor tyrosine kinases (RTKs) and the downstream
phosphatidylinositol 3-kinase (PI3K) signaling pathway have shown promising anticancer activity, …
phosphatidylinositol 3-kinase (PI3K) signaling pathway have shown promising anticancer activity, …
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt
from central tolerance, can generate robust immune responses 1 , 2 and can function as …
from central tolerance, can generate robust immune responses 1 , 2 and can function as …
p16INK4a induces an age-dependent decline in islet regenerative potential
The p16 INK4a tumour suppressor accumulates in many tissues as a function of advancing
age 1 , 2 , 3 . p16 INK4a is an effector of senescence 4 , 5 and a potent inhibitor of the …
age 1 , 2 , 3 . p16 INK4a is an effector of senescence 4 , 5 and a potent inhibitor of the …
Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets
Brain metastases are associated with a dismal prognosis. Whether brain metastases harbor
distinct genetic alterations beyond those observed in primary tumors is unknown. We …
distinct genetic alterations beyond those observed in primary tumors is unknown. We …
Mechanisms and therapeutic implications of hypermutation in gliomas
…, R Beroukhim, P Bandopadhayay, F Bielle, KL Ligon - Nature, 2020 - nature.com
A high tumour mutational burden (hypermutation) is observed in some gliomas 1 , 2 , 3 , 4 –
5 ; however, the mechanisms by which hypermutation develops and whether it predicts the …
5 ; however, the mechanisms by which hypermutation develops and whether it predicts the …